Thismakes RAD52 an appealing target for cancer therapy, as it will onlyhave key function in HR when BRCA1/2 are inactive: this will thereforehave a selective effect on cancer cells, without influencing healthcells. The gene discussed is BRCA1; the disease is cancer.